How many insider trades does FilingIQ track for ESLA?

FilingIQ tracks 5 Form 4 insider transactions for ESLA (Estrella Immunopharma, Inc.), covering filings from Sep 11, 2025 onwards. 2 of those were filed in the last 90 days.

Are ESLA insiders net buyers or net sellers?

Across the full Form 4 history for ESLA, 3 transactions (60%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ESLA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ESLA in?

Estrella Immunopharma, Inc. (ESLA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $55.46M.

ESLA insider trading

NasdaqCM Healthcare

Estrella Immunopharma, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

60% / 0%

Market cap

$55.46M

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.

Company website: www.estrellabio.com

ESLA insider activity at a glance

FilingIQ has scored 5 insider transactions for ESLA since Sep 11, 2025. The most recent filing in our index is dated Aug 18, 2026.

Across the full history, 3 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ESLA insider trades is 61.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ESLA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 934

UNITED THERAPEUTICS Corp

GH 194

Guardant Health, Inc.

BLLN 189

BillionToOne, Inc.

KYMR 186

Kymera Therapeutics, Inc.

Hims & Hers Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for ESLA?: FilingIQ tracks 5 Form 4 insider transactions for ESLA (Estrella Immunopharma, Inc.), covering filings from Sep 11, 2025 onwards. 2 of those were filed in the last 90 days.
Are ESLA insiders net buyers or net sellers?: Across the full Form 4 history for ESLA, 3 transactions (60%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ESLA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ESLA in?: Estrella Immunopharma, Inc. (ESLA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $55.46M.

Methodology & sources

Every ESLA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.